- category:Pipeline
Pipeline
Positive topline data reported in EyePoint's phase 2 wet AMD trial
EYP-1910 demonstrates a favorable safety profile in DAVIO 2 study, meeting all endpoints.
Pipeline
Aldeyra's NDA for reproxalap requires more studies, FDA says
Company response letter follows the submission of a special protocol assessment for a crossover trial.
Pipeline
Kodiak is restarting its tarcocimab clinical program for three retinal disease indications
Pipeline
FDA approves initiation of first inflammasome inhibitor trial for GA
Use of Kamuvudines via a sustained release delivery system could prevent the process that causes GA.
Pipeline
Pixium Vision releases 48-month study data for severe atrophic AMD
Trial results on the PRIMA Bionic Vision System indicate promising safety and efficacy.
Pipeline
EyesBio expands financing for advanced development of Restoret
Funding now totals $130 million, supporting the ongoing phase 1b/2a AMARONE trial.
Pipeline
FDA grants RMAT designation for Atsena's LAC1 gene therapy
Positive 6-month data on ATSN-101 supports designation; 12-month results expected by end of 2023.
Pipeline
Focusing in: Surgical innovation highlights at AAO
Eric Donnenfeld, MD, FAAO, FACS, shares clinical updates on two innovative technologies and his pick for a must-attend session.
Pipeline
Positive 1-year data reported in ALTITUDE gene therapy trial
Ongoing phase 2 trial reports potential for one-time injection in managing DR.
Pipeline
OnPoint Vision's IDE app for IOPCL Magnifier earns FDA approval
Paves the way for a phase 1 pivotal trial on AccuraSee, designed to securely pair with any pre-existing IOL located within the capsular bag.
Pipeline
Aldeyra and AbbVie agree to exclusive licensing option for reproxalap
Agreement follows FDA concerns regarding the DED investigational compound’s clinical data.
Pipeline
Enrollment concludes for ViaLase's pivotal POAG laser trial
First femtosecond laser image-guided high-precision trabeculectomy (FLigHT) offers the potential as a non-invasive treatment.
Pipeline
Ocular Therapeutix initiates first pivotal trial of implant for wet AMD
OTX-TKI offers the potential for long-term durability with fewer injections.
Pipeline
FDA clears Endogena's IND for GA investigational compound
A first-in-human study for EA-2351 is set to kick off in 2024.
Pipeline
Glaukos acquires global rights to Stuart Therapeutics' neuroprotection glaucoma asset
Proprietary therapeutic has been shown to function independently of IOP control.
Pipeline
Positive data released for Aviceda's phase 2/3 GA trial
Findings report on first three months of part 1 evaluating AVD-104 in the SIGLEC trial.
Pipeline
Aldeyra's reproxalap faces FDA concerns
Agency identifies substantive review issues with the dry eye disease candidate
Pipeline
New 6-month data evaluates AZR-MD-001 for MGD
Presented at AAOPT, latest findings follow previous 3-month data evaluating the efficacy of two dosages.
Pipeline
Positive 4-year data reported from phase 3 CHAMP study for pediatric myopia
Latest data on NVK002 builds on previous 3-year results released in May 2023.
Pipeline